Sleven, to add to that I think ANRN is an unborn among biotechs. The reason biotechs fail is because the science fails. If n that case nothing will fix the failure. In AMRN’s case, it’s a business execution and market development issue. If these two components fail, the asset is still valuable and someone will find a way to make it successful. All my opinion and no endorsement intended.
Market Data 
Markets 
AI
